Online first
Review paper
Published online: 2024-11-28
FIGO 2023 — too soon or just in time? Evolution or a revolution? Review of the newest endometrial cancer staging classification
1, 1, 23
, 4, 5, 6, 2
, 4, 5, 6, 2
DOI: 10.5603/gpl.102620
Pubmed: 39611468
Abstract
The FIGO staging system is an integral part of the therapeutic and treatment process in female genital tumors. It cements the knowledge gained to date to plan patient treatment prognosis and the course of the disease and compare treatment outcomes between centers in the most individualized yet systematic way. In response to these assumptions, the FIGO Committee on Gynaecological Oncology updated the endometrial cancer staging classification in June 2023. The new endometrial cancer staging classification includes multiple clinicopathological prognostic factors and molecular findings for the first time. In this review, we summarize the differences between the new and the old FIGO classification and comment on its everyday real-world application.
Keywords: endometrial cancerFIGO classificationendometrial cancer staging
References
- 24-corpus-uteri-fact-sheet.pdf. https://gco.iarc.who.int/media/globocan/factsheets/cancers/24-corpus-uteri-fact-sheet.pdf (25.02.2024).
- Cancer in Poland in 2020. https://onkologia.org.pl/sites/default/files/publications/2023-01/nowotwory_2020.pdf (10.12.2023).
- Chudecka-Głaz A, Łacko A, Nowakowski A, et al. Analiza problemu decyzyjnego Dostarlimab (Jemperli®) w leczeniu dorosłych pacjentek z nawrotowym lub zaawansowanym rakiem endometrium z DMMR/MSI-H, który uległ progresji w trakcie lub po zakończeniu wcześniejszego schematu leczenia zawierającego platynę: wersja 2.0. HTA Consulting. https://bipold.aotm.gov.pl/assets/files/zlecenia_mz/2022/134/AW/134_AW_OT.4231.72.2022_Jemperli_APD.pdf (10.12.2023).
- Levine DA. The Cancer Genome Atlas Research Network. Integrated genomic characterization of endometrial carcinoma. Nature. 2013; 497(7447): 67–73.
- Bidzinski M, Danska-Bidzinska A, Rychlik A, et al. Molecular classification of endometrial carcinoma, is it the new era of precision medicine? Ginekol Pol. 2022; 93(2): 163–167.
- Berek JS, Matias-Guiu X, Creutzberg C, et al. FIGO staging of endometrial cancer: 2023. Int J Gynaecol Obstet. 2023; 162(2): 383–394.
- Zaino RJ, Abendroth C, Yemelyanova A, et al. Endocervical involvement in endometrial adenocarcinoma is not prognostically significant and the pathologic assessment of the pattern of involvement is not reproducible. Gynecol Oncol. 2013; 128(1): 83–87.
- Höhn AK, Brambs CE, Hiller GG, et al. 2020 WHO classification of female genital tumors. Geburtshilfe Frauenheilkd. 2021; 81(10): 1145–1153.
- Concin N, Matias-Guiu X, Vergote I, et al. ESGO/ESTRO/ESP guidelines for the management of patients with endometrial carcinoma. Int J Gynecol Cancer. 2021; 31(1): 12–39.
- Bayramoglu D, Seçilmiş Kerimoğlu Ö, Bayramoğlu Z, et al. Classification of high-grade endometrium carcinomas using molecular and immunohistochemical methods. Ginekol Pol. 2023; 94(1): 3–11.
- Misiek M, Michalczyk K, Kukla-Jakubowska A, et al. Disease-free and overall survival implications of pelvic lymphadenectomy in endometrial cancer: a retrospective population-based single-center study. Cancers (Basel). 2023; 15(23).
- Talhouk A, McConechy MK, Leung S, et al. Confirmation of ProMisE: a simple, genomics-based clinical classifier for endometrial cancer. Cancer. 2017; 123(5): 802–813.
- Rychlik A, Bidzinski M. Molecular classification in endometrial cancer — are we ready? Ginekol Pol. 2023; 94(1): 1–2.
- Berek JS, Matias-Guiu X, Creutzberg C, et al. FIGO staging of endometrial cancer: 2023. J Gynecol Oncol. 2023; 34(5): e85.
- McCluggage WG, Bosse T, Gilks CB, et al. FIGO 2023 endometrial cancer staging: too much, too soon? Int J Gynecol Cancer. 2024; 34(1): 138–143.
- Bokhman JV. Two pathogenetic types of endometrial carcinoma. Gynecol Oncol. 1983; 15(1): 10–17.
- Spoor E, Cross P. Audit of endometrial cancer pathology for a regional gynecological oncology multidisciplinary meeting. Int J Gynecol Pathol. 2019; 38(6): 514–519.
- McCluggage WG, Bosse T, Gilks CB, et al. FIGO 2023 endometrial cancer staging: too much, too soon? Int J Gynecol Cancer. 2024; 34(1): 138–143.
- Gravbrot N, Weil CR, DeCesaris CM, et al. Differentiation of survival outcomes by anatomic involvement and histology with the revised 2023 International Federation of Gynecology and Obstetrics staging system for endometrial cancer. Eur J Cancer. 2024; 201: 113913.
- Schwameis R, Fanfani F, Ebner C, et al. Verification of the prognostic precision of the new 2023 FIGO staging system in endometrial cancer patients — an international pooled analysis of three ESGO accredited centres. Eur J Cancer. 2023; 193: 113317.
- Talhouk A, McConechy MK, Leung S, et al. A clinically applicable molecular-based classification for endometrial cancers. Br J Cancer. 2015; 113(2): 299–310.
- Jamieson A, McConechy MK, Lum A, et al. Harmonized molecular classification; assessment of a single-test ProMisE NGS tool. Gynecol Oncol. 2023; 175: 45–52.
- Piulats J, Guerra E, Gil-Martín M, et al. Molecular approaches for classifying endometrial carcinoma. Gynecol Oncol. 2017; 145(1): 200–207.
- Berek JS, Matias-Guiu X, Creutzberg C, et al. FIGO staging of endometrial cancer: 2023. Int J Gynaecol Obstet. 2023; 162(2): 383–394.
- Leitao MM. 2023 changes to FIGO endometrial cancer staging: counterpoint. Gynecol Oncol. 2024; 184: 146–149.
- Amin MB, Greene FL, Edge SB, et al. The eighth edition AJCC cancer staging manual: continuing to build a bridge from a population-based to a more “personalized” approach to cancer staging. CA Cancer J Clin. 2017; 67(2): 93–99.
- Beltz A, Gösswein D, Zimmer S, et al. Staging of oropharyngeal squamous cell carcinoma of the head and neck: prognostic features and power of the 8th edition of the UICC staging manual. Eur J Surg Oncol. 2019; 45(6): 1046–1053.
